J 2020

HPV, protein p16 and squamous cell carcinoma of the oral cavity

BLAHÁK, Jiří, Jiří ZELINKA, Jaromír GUMULEC, Ctirad MACHÁČEK, Zdeněk DANĚK et. al.

Basic information

Original name

HPV, protein p16 and squamous cell carcinoma of the oral cavity

Authors

BLAHÁK, Jiří (203 Czech Republic, guarantor, belonging to the institution), Jiří ZELINKA (203 Czech Republic, belonging to the institution), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Ctirad MACHÁČEK (203 Czech Republic, belonging to the institution), Zdeněk DANĚK (203 Czech Republic, belonging to the institution) and Oliver BULIK (203 Czech Republic, belonging to the institution)

Edition

Biomedical Papers, Olomouc, Univerzita Palackého v Olomouci, 2020, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.245

RIV identification code

RIV/00216224:14110/20:00116360

Organization unit

Faculty of Medicine

UT WoS

000595645600011

Keywords in English

oral squamous cell carcinoma; oral cancer; HPV; human papilloma virus; p16

Tags

International impact, Reviewed
Změněno: 5/1/2021 12:04, Mgr. Tereza Miškechová

Abstract

V originále

Background: Squamous cell carcinoma of the oral cavity is generally caused by the long-term impact of known risk factors, e.g. tobacco and alcohol, along with chronic traumatisation. A number of studies now implicate HPV infection in head and neck tumour carcinogenesis but the exact role of HPV infection in the oral cavity remains unclear. Methods: In this study, we evaluated 78 patients with oral squamous cell carcinoma (OSCC) for the expression of protein p16 in the context of HPV positivity and its influence on the overall survival rate, disease location, staging and grading. Results: Regarding the tumour location, no significant difference was found between HPV-positive and HPV-negative patients, nor between p16-positive and p16-negative patients. There was also no trend in terms of HPV status and stage, and differentiation of carcinoma. There was no effect on HPV-positive patients relative to the time to progression (P=0.84) and overall survival rate (P=0.78). P16 positivity was not found to have an effect on the overall survival rate of patients (P=0.41) and there was no correlation between p16 positivity relative to the time to progression (P=0.66). Conclusions: In summary, the data suggest that there is no effect of HPV status on the prognosis of OSCC patients compared to other HNSCC locations.